NorthStar Medical Radioisotopes and YAP Therapeutics, Inc. have entered a collaboration to develop advanced radiopharmaceuticals targeting cancer and other chronic conditions. The partnership leverages NorthStar’s expertise in medical radioisotope production and YAP’s biologic and regenerative medicine platforms. Under this agreement,
NorthStar Medical Radioisotopes, LLC, a leader in radiopharmaceuticals, has signed a supply agreement with Ariceum Therapeutics, a biotech company specialising in radiopharmaceutical cancer treatments. The agreement ensures Ariceum receives non-carrier-added, high-purity Actinium-225 (Ac-225), a critical isotope for advancing its therapeutic
NorthStar Medical Radioisotopes and PeptiDream Inc. have entered a strategic collaboration to advance peptide-RI conjugate programs, focusing initially on PDRadiopharma’s CA9 therapeutic asset. PDRadiopharma, a radiopharmaceuticals company in Japan and a wholly owned subsidiary of PeptiDream, will gain access to
Cellectar Biosciences has announced a decade-long supply agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225 (Ac-225), a key radioisotope in cancer treatment. This agreement is set to provide Cellectar with a stable Ac-225 supply, enabling
NorthStar Medical Radioisotopes, a radiopharmaceutical Contract Development and Manufacturing Organization, officially opened its new Dose Manufacturing Center in Beloit, Wisconsin. The state-of-the-art facility will increase NorthStar’s capacity to support biopharmaceutical companies in the development and production of critical radioisotopes used
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
